Metabolic

Featured Article

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Latest Features

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Latest News

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

Total cardiovascular event reduction may represent a more comprehensive metric to assess alirocumab clinical efficacy after acute coronary syndrome.

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

AKCEA-APO(a)-LRX is efficient and safe in patients with established cardiovascular disease and elevated levels of lipoprotein(a).

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

Compared with evolocumab, the addition of ezetimibe to statin therapy is a major cost-saving strategy for preventing cardiovascular (CV) death in patients with T2D and an established CV disease.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

LDL-C Testing Associated With Lower Achieved LDL-C Levels

LDL-C Testing Associated With Lower Achieved LDL-C Levels

Investigators sought to determine whether clinician lipid testing practices were consistent with ACC/AHA 2013 recommended testing guidelines for LDL cholesterol.

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Hyperglycemia, obesity, and hypertriglyceridemia are negatively related to cardiovascular autonomic neuropathy indices.

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Repatha is a proprotein convertase subtilisin/kexin type 9 inhibitor.

Sign Up for Free e-Newsletters